Can-Fite BioPharma (CANF) Non-Current Assets (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Non-Current Assets came in at $74000.0 in Q4 2025, down 46.38% YoY from $138000.0 in Q4 2024, and down 22.92% on a QoQ basis from $96000.0 in Q2 2025.
Can-Fite BioPharma (CANF) Non-Current Assets (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Non-Current Assets data on file, last reported at $74000.0 in Q4 2025.
- Quarterly Non-Current Assets fell 46.38% year-over-year to $74000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $74000.0 (down 46.38% YoY) and the FY2025 annual result came in at $74000.0, down 46.38% from the prior year.
- Non-Current Assets slipped to $74000.0 in Q4 2025, from $96000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $185000.0 in Q4 2021 to a low of $74000.0 in Q4 2025.
- A 5-year average of $125812.5 and a median of $124500.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets jumped 70.37% — and 2025, when it plunged 46.38%.
- Tracing CANF's Non-Current Assets over 5 years: stood at $185000.0 in 2021, then tumbled by 31.89% to $126000.0 in 2022, then tumbled by 35.71% to $81000.0 in 2023, then jumped by 70.37% to $138000.0 in 2024, then slumped by 46.38% to $74000.0 in 2025.
- The last three Non-Current Assets figures came in at $74000.0 (Q4 2025), $96000.0 (Q2 2025), and $138000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 74,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 105,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Mar 31, 2023 | 110,000.00 |
| Dec 31, 2022 | 126,000.00 |
| Sep 30, 2022 | 141,000.00 |
| Jun 30, 2022 | 157,000.00 |
| Mar 31, 2022 | 174,000.00 |
| Dec 31, 2021 | 185,000.00 |
| Sep 30, 2021 | 165,000.00 |
| Jun 30, 2021 | 127,000.00 |
| Mar 31, 2021 | 117,000.00 |
| Dec 31, 2020 | 123,000.00 |
| Jun 30, 2020 | 96,000.00 |
| Dec 31, 2019 | 1.03 Mn |
| Sep 30, 2019 | 1.80 Mn |